Treatment Intensification for Locally Advanced Rectal Cancer: Impact on Pathological Complete Response and Outcomes

Pathological complete response (pCR) and clinical outcomes [overall survival (OS), disease-free survival (DFS), locoregional control (LC)] were evaluated in a single-institution experience of different schedules of neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancer...

Full description

Saved in:
Bibliographic Details
Published in:In vivo (Athens) 2020-05, Vol.34 (3), p.1223-1233
Main Authors: DI Tommaso, Monica, Rosa, Consuelo, Caravatta, Luciana, Augurio, Antonietta, Borzillo, Valentina, DI Santo, Sara, Perrotti, Francesca, Taraborrelli, Maria, Cianci, Roberta, Innocenti, Paolo, DI Sebastiano, Pierluigi, Colasante, Antonella, Angelucci, Domenico, Basti, Massimo, Sindici, Giulia, Mazzola, Lorenzo, Pizzicannella, Giuseppe, DI Bartolomeo, Nicola, Marchioni, Michele, DI Nicola, Marta, Genovesi, Domenico
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Chemoradiotherapy
Combined Modality Therapy
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Rectal Neoplasms - mortality
Rectal Neoplasms - pathology
Rectal Neoplasms - therapy
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pathological complete response (pCR) and clinical outcomes [overall survival (OS), disease-free survival (DFS), locoregional control (LC)] were evaluated in a single-institution experience of different schedules of neoadjuvant chemoradiotherapy (CRT) for patients with locally advanced rectal cancer (LARC). Data for 322 patients with LARC were retrospectively analyzed. pCR was evaluated according to Mandard tumor regression grade (TRG). The Kaplan-Meier method was used to estimate OS, DFS and LC. Three hundred and three (94.1%) patients underwent surgery. pCR was observed in 81 patients (26.7%), with TRG1-2 rate of 41.8%. The 5- and 10-year OS, DFS and LC rates were 82.5%±2.5% and 65.5%±3.8%, 81.2%±2.4% and 79.3%±2.9%, 93.1%±1.7% and 90.5%±2.1%, respectively. Neoadjuvant CRT in LARC patients resulted in favorable long-term oncological outcomes, with a high pCR rate and acceptable toxicity.
ISSN:0258-851X
1791-7549
DOI:10.21873/invivo.11896